Transitioned to commercial scale-up with first revenues from Follicopeptide Gel Serum and expanded the product portfolio. Liquidity was strengthened by a SEK 12.1 million share issue, while operating losses narrowed year-over-year. Risks remain around financing and commercialization progress.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.